Genentech
Genentech articles from Informachine.Genentech rejects Roche’s $43.7-billion takeover offer as too low
13 Aug 2008
Biotechnology giant Genentech Inc today rejected a $43.7-billion takeover bid from its majority shareholder, Roche Holding AG, as too low, while saying it would be open to a higher proposal.
Stay ahead with Informachine News Trackers! Follow your selected sources, track business news with relevant keywords, and organize seamlessly using labels and bookmarks.
Get the business updates you need, fast, focused, and tailored just for you. Save time, stay informed, and never miss a beat!
Latest articles on Genentech from Informachine
Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME’ Campaign
27 Apr 2026
Discover the latest news about our company, our products, our policies, and our people.
Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS
27 Apr 2026
Discover the latest news about our company, our products, our policies, and our people.
Genentech’s Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD
27 Apr 2026
Discover the latest news about our company, our products, our policies, and our people.
FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus
27 Apr 2026
Discover the latest news about our company, our products, our policies, and our people.
Genentech Provides Update on Phase III persevErA Study in ER-Positive Advanced Breast Cancer
26 Mar 2026
Discover the latest news about our company, our products, our policies, and our people.
New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech’s Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus
06 Mar 2026
Discover the latest news about our company, our products, our policies, and our people.
Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity
06 Mar 2026
Discover the latest news about our company, our products, our policies, and our people.
Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)
04 Mar 2026
Discover the latest news about our company, our products, our policies, and our people.
Genentech Announces Positive Phase III Results for Gazyva in Primary Membranous Nephropathy, Marking a Significant Milestone in This Autoimmune Disease
16 Feb 2026
Discover the latest news about our company, our products, our policies, and our people.
Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)
08 Feb 2026
Discover the latest news about our company, our products, our policies, and our people.
